COMPANY PROFILE

1stbio

Explore full profile

1ST BIOTHERAPEUTICS, INC – 퍼스트바이오, 테라퓨틱스, 1stbio

Yongin-si, South KoreaFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About 1stbio

1STBIO is a pioneering biopharmaceutical company dedicated to developing breakthrough therapies aimed at addressing unmet medical needs. The company focuses on the discovery and development of first-in-class therapeutic candidates with a high likelihood of clinical success. With a team of 24 experts in biochemistry, medicinal chemistry, pharmacology, and business development, 1STBIO operates in the highly specialized field of drug discovery and development. The company serves patients who require novel medicines, particularly in the areas of neurodegenerative diseases and other complex conditions. Operating within the biopharmaceutical market, 1STBIO's business model revolves around rigorous research and development (R&D) activities, forming strategic partnerships, and leveraging a robust network of scientific advisors and academic collaborations. Revenue is generated through the successful development and commercialization of innovative therapies, as well as potential licensing agreements and partnerships with larger pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Yongin-si, South Korea
Employees: 3
Open positions: None listed
Dealroom signal: 54.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES D✓Equity / VC	Jan 2026	$27M	$106M	Mirae Asset Capital · Ligachem Bio · LegoChem Biosciences · CKD Venture Capital Corporation	↗
SERIES B✓Equity / VC	Jul 2020	$15M	$59M	SmileGate Investment	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

1stbio website traffic

Latest recorded traffic for 1stbio is 3.1K monthly website visits, down 61.3% over the last three months. 1stbio's team grew 200% over the past year.

Latest monthly visits3.1K 3-month web change-61.3% 1-year team growth+200%

Monthly website visitsJun 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
JLJunhe LeagueRecombinant protein drug developer	Hangzhou, China	Operational	—	$55M	$110M
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
CGCold GenesysOncolytic immunotherapy \| CG0070 \| Cold Genesys	Santa Ana, United States	Operational
ANAnagenexBiotechnology company building a novel platform for drug discovery focusing on difficult targets	San Francisco, United States	Operational
MPMaaT PharmaDevelops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments	Lyon, France	Operational
CSCaris Life SciencesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics	Irving, United States	Operational
MBMereo BiopharmaAcquiring and developing therapeutics for rare diseases and oncology	London, United Kingdom	Operational
ATArrakis TherapeuticsPioneering biopharmaceutical company	Waltham, United States	Operational